SYNCOMF

Syncom Formulation (India) Share PriceSyncom Formulation (India)

₹5.96
-0.03 (-0.5%)
As on 25 March, 2023 | 07:04 BSE: 524470 NSE: SYNCOMF

Syncom Formulation (India) Performance

Day Range

  • Low
  • High

52 Week Range

  • Low
  • High
  • Open Price
  • Previous Close
  • Volume

Start SIP in Syncom Formulation (India)

Start SIP

Syncom Formulation (India) Share Price

  • Over 1 Month -8.87%
  • Over 3 Month -38.81%
  • Over 6 Month -30.37%
  • Over 1 Year -50.58%

Syncom Formulation (India) Key Statistics

P/E Ratio 34.2
PEG Ratio -1.3
Market Cap Cr 560
Price to Book Ratio 2.5
EPS 0.2
Dividend 0.5
Relative Strength Index 31.44
Money Flow Index 20.4
MACD Signal -0.33
Average True Range 0.31

Syncom Formulation (India) Investment Rating

  • Master Rating:
  • Syncom Formulations India has an operating revenue of Rs. 221.51 Cr. on a trailing 12-month basis. An annual revenue de-growth of -8% needs improvement, Pre-tax margin of 12% is healthy, ROE of 8% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 57 which is a POOR score indicating inconsistency in earnings, a RS Rating of 7 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 91 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of E is the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Syncom Formulation (India) Financials
IndicatorDec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 57545158
Operating Expenses Qtr Cr 51504856
Operating Profit Qtr Cr 6432
Depreciation Qtr Cr 1111
Interest Qtr Cr 1111
Tax Qtr Cr 2211
Net Profit Qtr Cr 4445

Syncom Formulation (India) Technicals

EMA & SMA

Current Price
₹5.96
-0.03 (-0.5%)
  • Bullish Moving Average
  • ___
  • 0
  • Bearish Moving Average
  • ___
  • 16
  • 20 Day
  • 6.3
  • 50 Day
  • 6.89
  • 100 Day
  • 7.44
  • 200 Day
  • 8.03
  • 20 Day
  • 6.27
  • 50 Day
  • 7.05
  • 100 Day
  • 7.64
  • 200 Day
  • 8.04

Syncom Formulation (India) Resistance and Support

PIVOT
₹6.03
Resistance
First Resistance 6.12
Second Resistance 6.24
Third Resistance 6.33
RSI 31.44
MFI 20.4
MACD Single Line -0.33
MACD -0.31
Support
First Resistance 5.91
Second Resistance 5.82
Third Resistance 5.7

Syncom Formulation (India) Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 1,118,591 69,800,078 62.4
Week 1,442,138 88,806,883 61.58
1 Month 1,528,948 96,858,880 63.35
6 Month 2,433,726 136,093,943 55.92

Syncom Formulation (India) Result Highlights

Syncom Formulation (India) Synopsis

NSE-Medical-Diversified

Syncom Formul. is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company’s Total Operating Revenue is Rs. 219.66 Cr. and Equity Capital is Rs. 86.25 Cr. for the Year ended 31/03/2022. Syncom Formulation (India) Ltd. is a Public Limited Listed company incorporated on 21/06/1988 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1988PLC047759 and registration number is 047759.
Market Cap 559
Sales 222
Shares in Float 46.06
No of funds 2
Yield 0.5
Book Value 2.31
U/D Vol ratio 0.3
LTDebt / Equity
Alpha -0.2
Beta 0.86

Syncom Formulation (India)

Owner NameDec-22Sep-22Jun-22Mar-22
Promoters 50.57%50.57%50.57%
Mutual Funds
Foreign Portfolio Investors
Individual Investors 45.02%44.92%44.86%
Others 4.41%4.51%4.57%

Syncom Formulation (India) Management

Name Designation
Mr. Kedarmal Shankarlal Bankda Executive Chairman
Mr. Vijay Shankarlal Bankda Managing Director
Mrs. Rinki Ankit Bankda Whole Time Director
Mr. Krishna Das Neema Independent Director
Mr. Praveen Jindal Independent Director
Mr. Vinod Kumar Kabra Independent Director
Mrs. Ruchi Jindal Addnl. Independent Woman Director

Syncom Formulation (India) Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Syncom Formulation (India) MF Shareholding

Name Amount(cr)
Motilal Oswal S&P BSE Healthcare ETF 6

Syncom Formulation (India) FAQs

What is Share Price of Syncom Formulation (India) ?

Syncom Formulation (India) share price is ₹5 As on 25 March, 2023 | 06:50

What is the Market Cap of Syncom Formulation (India) ?

The Market Cap of Syncom Formulation (India) is ₹560.2 Cr As on 25 March, 2023 | 06:50

What is the P/E ratio of Syncom Formulation (India) ?

The P/E ratio of Syncom Formulation (India) is 34.2 As on 25 March, 2023 | 06:50

What is the PB ratio of Syncom Formulation (India) ?

The PB ratio of Syncom Formulation (India) is 2.5 As on 25 March, 2023 | 06:50

Q2FY23

Start Investing Now!

Open Free Demat Account in 5 mins

Enter Valid Mobile Number